Emergent Biosolutions - Stock Price History | EBS

Historical daily share price chart and data for Emergent Biosolutions since 2022 adjusted for splits. The latest closing stock price for Emergent Biosolutions as of September 30, 2022 is 20.99.
  • The all-time high Emergent Biosolutions stock closing price was 134.94 on August 13, 2020.
  • The Emergent Biosolutions 52-week high stock price is 55.21, which is 163% above the current share price.
  • The Emergent Biosolutions 52-week low stock price is 20.06, which is 4.4% below the current share price.
  • The average Emergent Biosolutions stock price for the last 52 weeks is 37.74.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Emergent Biosolutions Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 67.7216 93.1000 125.1900 33.1100 43.4700 -51.48%
2020 83.1653 54.0000 134.9400 49.3400 89.6000 66.08%
2019 51.8647 57.7000 66.1600 39.9200 53.9500 -8.99%
2018 56.2235 47.9700 73.2400 44.4400 59.2800 27.57%
2017 34.9138 33.2300 47.7500 28.3000 46.4700 41.50%
2016 32.0599 35.6916 41.4356 24.6000 32.8400 -12.40%
2015 29.9068 25.2062 37.7437 24.5784 37.4907 46.93%
2014 22.3056 22.5075 26.3212 18.6657 25.5154 18.44%
2013 16.1497 15.8358 22.4419 12.2564 21.5424 43.33%
2012 14.1415 15.9295 17.1852 12.0971 15.0300 -4.75%
2011 19.1232 22.2826 23.4071 14.0742 15.7796 -28.22%
2010 15.9711 12.9404 22.3014 12.6125 21.9828 72.63%
2009 14.8789 23.5101 24.6065 9.0142 12.7343 -47.95%
2008 11.5790 4.7695 24.4659 4.6758 24.4659 416.01%
2007 9.7116 10.5885 15.9108 4.4134 4.7414 -54.66%
2006 10.1429 10.9633 10.9633 9.1548 10.4573 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.036B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.119B 9.29
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.856B 0.00
QIAGEN (QGEN) Netherlands $9.360B 15.67
Ginkgo Bioworks Holdings (DNA) United States $5.587B 0.00
Arcus Biosciences (RCUS) United States $1.842B 35.96
Myovant Sciences (MYOV) United Kingdom $1.684B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Enzo Biochem (ENZ) United States $0.107B 0.00
Gelesis Holdings (GLS) United States $0.078B 0.00
SQZ Biotechnologies (SQZ) United States $0.065B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00